Shots:

• Verge to receive ~$25M as up front- equity investment- and near-term payments in addition to ~$694M as milestone and royalties
• The collaboration will utilize Verge’s AI-driven all-in-human platform to identify new targets. Lilly may select up to four identified targets to advance it into clinical development and commercialization
• Verge Genomics retains all rights to its lead program & plans to start clinical trials for its lead program that targets PIKfyve for ALS in 2022

  Ref: Businesswire | Image: Venture Beat